Allergic contact dermatitis to topical prodrugs used in photodynamic therapy

Helen Cordey (Lead / Corresponding author), Sally Ibbotson

Research output: Contribution to journalLetter

4 Citations (Scopus)
168 Downloads (Pure)

Abstract

Topical photodynamic therapy (PDT) is a well-established treatment for actinic keratosis, Bowen's disease and superficial basal cell carcinoma and its use has also been explored for a variety of other indications.(1,2,3) Treatment involves application of a pro-drug (either 5-aminolaevulinic acid (ALA) or its methlyester, methylaminolevulinate (MAL)) which is preferentially taken up by dysplastic or neoplastic cells and converted into the active photosensitiser protoporphyrin IX (PPIX). Subsequent activation of PPIX by red light results in the production of cytotoxic oxygen species, inflammation and relatively selective diseased tissue destruction. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)320-322
Number of pages3
JournalPhotodermatology, Photoimmunology & Photomedicine
Volume32
Issue number5-6
Early online date7 Jul 2016
DOIs
Publication statusPublished - 15 Aug 2016

    Fingerprint

Cite this